Program

The Best of ASCO Program presents the scientific and educational highlights of the ASCO Annual Meeting selected from the year’s notable abstracts. Please see the agenda for more information.

Meeting Chair: David C. Smith, MD, University of Michigan

7:00 AM–3:10 PM Exhibits Open

7:00 AM–7:55 AM

Registration and Continental Breakfast

7:55 AM–8:00 AM

Welcome and Chair Remarks

David C. Smith, MD
University of Michigan

8:00 AM–8:40 AM

Gastrointestinal (Colorectal) Cancer

George A. Fisher, MD, PhD
Stanford University

Abstract LBA1: Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. (Qian Shi)
Abstract 3503: Primary (1°) tumor location is an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). (Alan Venook)
Abstract 3505: Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). (Scott Kopetz)
Abstract 3507: Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. (Ricky Sharma)

8:40 AM–9:20 AM

Gastrointestinal (Noncolorectal) Cancer

William P. Harris, MD
Seattle Cancer Care Alliance

Abstract 4001: Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). (Ann-Lii Cheng)
Abstract 4006: Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. (John Primrose)
Abstract 4007: Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma. (Howard Safran)
Abstract 4014: Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (Yelena Janjigian)

9:20 AM–9:40 AM

Panel Question and Answer: Gastrointestinal Cancers

George A. Fisher, MD, PhD
Stanford University

William P. Harris, MD
Seattle Cancer Care Alliance

9:40 AM–10:00 AM

Break

10:00 AM–10:40 AM

Breast Cancer—Local/Regional/Adjuvant

Heather L. McArthur, MD
Cedars-Sinai Medical Center

Abstract LBA500: APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). (Gunter Von Minckwitz)
Abstract 504: Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Nadia Harbeck)
Abstract 506: Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. (Rita Nanda)
Abstract 508: Mastectomy rates in relation to adoption of a margin guideline. (Monica Morrow)

10:40 AM–11:20 AM

Breast Cancer—Metastatic

Virginia G. Kaklamani, MD
University of Texas Health Science Center at San Antonio

Abstract LBA4: OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). (Mark Robson)
Abstract 1000: MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy (George Sledge)
Abstract 1001: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). (Richard Finn)
Abstract 1008: Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (Sylvia Adams)

11:20 AM–11:40 AM

Panel Question and Answer: Breast Cancer

Heather L. McArthur, MD
Cedars-Sinai Medical Center

Virginia G. Kaklamani, MD
University of Texas Health Science Center at San Antonio

11:40 AM–12:30 PM

Complimentary Boxed Lunch

11:50 AM–12:20 PM

Meet the Professor Roundtables
For more information, visit Onsite Networking.

12:30 PM–1:10 PM

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Matthew J. Wieduwilt, MD, PhD
University of California, San Diego

Abstract 7000: Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF). (Ruben Mesa)
Abstract 7002: Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. (Jorge Cortes)
Abstract 7004: Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study. (Eytan Stein)
Abstract 7006: Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)/AIDS Malignancy Consortium (AMC-080) trial. (Richard Ambinder)

1:10 PM–1:50 PM

Hematologic Malignancies—Plasma Cell Dyscrasia

Nina Shah, MD
University of California, San Francisco

Abstract 8000: Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study. (Andrzej Jakubowiak)
Abstract 8003: Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). (Francesca Maria Gay)
Abstract 8005: Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. (Noopur Raje)

1:50 PM–2:30 PM

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Jeffrey A. Jones, MD, MPH
The Ohio State University

Abstract 7500: First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. (Ian Flinn)
Abstract 7503: A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). (Amy Ruppert)
Abstract 7506: Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. (Michael Pfreundschuh)
Abstract 7508: Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Bone Marrow Transplant Research (CIBMTR) analysis. (James Godfrey)

2:30 PM–2:50 PM

Panel Question and Answers: Hematologic Malignancies

Matthew J. Wieduwilt, MD, PhD
University of California, San Diego

Nina Shah, MD
University of California, San Francisco

Jeffrey A. Jones, MD, MPH
The Ohio State University

2:50 PM–3:10 PM Break
3:10 PM–4:30 PM

Town Hall: Practice Realities in a Shifting Policy Landscape

John Cox, DO, FACP, FASCO, MBA
University of Texas Southwestern

Daniel Mirda, MD
Annadell Medical Group

Therese Mulvey, MD, FASCO
Massachusetts General Hospital Cancer Center